Julia Malato

α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas

Eswari Dodagatta-Marri, Dominique S. Meyer, Melissa Quino Reeves et al. · Journal for ImmunoTherapy of Cancer · 2019 · 178 citations · Full text

Life Sciences, Immunology, Oncology +17

MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2–Altered Advanced Solid Tumors

Christopher J. Sweeney, John D. Hainsworth, Ron Bose et al. · Journal of Clinical Oncology · 2023 · 67 citations · Full text

Medicine, Oncology, Solid Tumor Pharmacotherapy +1

Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma

Hector H. Huang, Ian Ferguson, Alexis M. Thornton et al. · Nature Communications · 2020 · 47 citations · Full text

Life Sciences, Molecular Biology, Oncology +17

ERpS294 is a biomarker of ligand or mutational ERα activation and a breast cancer target for CDK2 inhibition

Gary K. Scott, David Chu, Ravneet Kaur et al. · Oncotarget · 2016 · 16 citations · Full text

Medicine, Cancer Biology, Oncology +17

<i>In Vitro-In Vivo</i> Correlation for the Degradation of Tetra-PEG Hydrogel Microspheres with Tunable <i>β</i>-Eliminative Crosslink Cleavage Rates

Jeff Henise, Shaun D. Fontaine, Brian R. Hearn et al. · International Journal of Polymer Science · 2019 · 10 citations · Full text

Engineering, Bioengineering, Biomedical Engineering +15